PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression

Conclusion: PRMT5 functionally associates with EZH2 to promote CRC progression through epigenetically repressing CDKN2B expression. Thus, our findings raise the possibility that combinational intervention of PRMT5 and EZH2 may be a promising strategy for CRC therapy.

Source: Theranostics - April 19, 2021 Category: Molecular Biology Authors: Liu Yang, Da-wei Ma, Yue-peng Cao, Dong-zheng Li, Xin Zhou, Ji-feng Feng, Jun Bao Tags: Research Paper Source Type: research